肝门部胆管癌诊治的研究

The diagnosis and management of hilar cholangiocarcinoma

目的探讨提高肝门部胆管癌诊疗的方法。方法术前对 2 0例患者行血清CA19 9、CA2 4 2、CEA测定 ,手术方式分别为根治性切除和各种非根治性手术 ,并对 89% (5 1/ 5 7)患者进行随访。结果CA19 9对肝门部胆管癌术前诊断的敏感性和特异性分别为 78%和 90 % ,有 4 7% (2 7/5 7)的患者获得根治性切除 ,其 1年生存率为 96 % ,3年生存率为 32 %。结论血清CA19 9值检测有助于术前诊断和疗效的判断 。

ObjectiveTo evaluate the diagnostic and therapeutic methods for hilar cholangiocarcinoma(HCC). Methods In 20 HCC patients serum CA19 9, CA242, CEA were determined preoperatively. A total of 57 HCC patients underwent surgery. Postoperatively 89% (51/57) patients were followed up. Results The sensitivity and specificity of CA19 9 for preoperative diagnosis were 78% and 90%, respectively. 47%(27/57) patients underwent radical resection with 1, 3 year survival rates of 96% and 32%. ConclusionThe results showed that CA19 9 is helpful for the diagnosis of hilar cholangiocarcinoma. Radical resection is effective for prolonging the long term survival in patients with HCC.